The only AI-focused technology company with comprehensive precision pathology solutions
We develop robust, versatile precision pathology solutions with our deep computational and medical expertise.
We leverage data from more than 15 million annotations provided by our proprietary and crowd-sourced pathology network of over 450 pathologists, and a vast library of archived data to rigorously train and validate our AI-based models.
This allows us to deliver quality and transformative tools for pathologists that can help accelerate drug development, improve confidence in the accuracy of diagnosis, and get life-saving therapies to patients more quickly.
Our mission at PathAI is to improve patient outcomes with AI-powered pathology through:
More Accurate Diagnosis
Matching Patients with the Most Effective Treatments
More Life-Saving Drug Approvals
Leadership Team
Our leadership team combines industry-leading expertise across diverse fields – engineering, machine learning, life sciences, medicine, regulatory, strategy, and operations – to help drive the PathAI mission forward with everyone in our organization.
PathAI has established itself as a leader in AI-powered precision pathology through significant moments that accelerated growth
2016 - Founded
Founded in 2016, our Co-Founders identified the need for technology applied to pathology to reduce error rates, increase accuracy and reproducibility.
2019 - Received ISO 13485 and ISO 27001 Certifications
PathAI received certification of its quality management system for compliance with ISO 13485 and MDSAP for US regulations that validates its approach to produce safe and effective medical device software to support pathologists. PathAI also received its ISO 27001 certification, one of the highest internationally-recognized standards for information security management systems.
2019 - First Abstract Published in Journal of Clinical Oncology
PathAI's first published abstract titled CD8+ T cells in tumor parenchyma and stroma by image analysis (IA) and gene expression profiling (GEP): Potential biomarkers for immuno-oncology (I-O) therapy, is released for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
2020 - First Patents Issued
PathAI is issued its first two patents, which teach predicting a survival time of a patient and predicting tissue characteristics for a pathology image.
2020 - First Manuscript Published in Hepatology
PathAI's first manuscript titled Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH, is published in Hepatology, Journal of the American Association for the Study of Liver Diseases (AASLD).
2021 - Secured $165M Series C Funding
PathAI raised $165 million in Series C funding. This round fueled PathAI’s commercial reach in our research and development capabilities.
2021 - Expanded into Clinical Diagnostics
PathAI entered clinical diagnostics through the acquisition of Poplar Healthcare, an industry-leading independent anatomic pathology laboratory services provider.
2022 - In-house BioPharma Lab Built
PathAI builds in-house CAP/CLIA-certified GCLP histopathology lab to fully support end-to-end clinical trials for its BioPharma partners.
2022 - Received FDA 510(k) Clearance for AISight Dx
PathAI received FDA 510(k) clearance and CE Mark for its digital pathology platform, AISight Dx, which can be used for primary diagnosis in clinical settings.
2024 - Announced Strategic Partnership with Quest Diagnostics
Partnership with Quest Diagnostics included sale of PathAI Diagnostics and licensing of AISight platform.
Get In Touch
Interested in learning more about PathAI and how we're transforming pathology?